Avidity Biosciences定价6亿美元股票发行

2025-09-12 12:43

Avidity Biosciences (NASDAQ:RNA) has priced an upsized offering of 15M shares at $40 each to raise gross proceeds of $600M.
In addition, the biopharmaceutical company has granted the underwriters a 30-day option to purchase up to an additional 2.25M shares. The offering is expected to close on or about September 15, 2025, subject to the satisfaction of customary closing conditions.
Proceeds, together with its existing cash, will be used to advance the development of its three late-stage clinical programs, to build appropriate commercial inventory levels to support multiple potential launches, to expand its commercial infrastructure, to progress R&D associated with its AOC platform, and for working capital and general corporate purposes.
Source: Press Release

More on Avidity Biosciences